|
|
Volumn 346, Issue 6212, 2014, Pages 908-911
|
|
A dose of reality
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
BRINCIDOFOVIR;
CYTOKINE;
FAVIPIRAVIR;
LIVER ENZYME;
TKM EBOLA;
UNCLASSIFIED DRUG;
VIRUS ANTIBODY;
VIRUS DNA;
VIRUS RNA;
ZMAPP;
CYTOSINE;
PHOSPHONIC ACID DERIVATIVE;
ADENOVIRUS INFECTION;
ANTIVIRAL THERAPY;
BLOOD DONOR;
CYTOKINE PRODUCTION;
CYTOMEGALOVIRUS INFECTION;
DEMOCRATIC REPUBLIC CONGO;
DNA REPLICATION;
DRUG SAFETY;
EBOLA HEMORRHAGIC FEVER;
EBOLA VIRUS;
EUROPE;
EXPERIMENTAL THERAPY;
GUINEA PIG MODEL;
HEALTH CARE QUALITY;
HUMAN;
INFLAMMATION;
MEDICAL ETHICS;
MONKEY MODEL;
MORTALITY;
MOUSE MODEL;
NONHUMAN;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SCIENTIST;
SURVIVAL;
SURVIVAL RATE;
SURVIVAL TIME;
UNITED STATES;
VIRUS IMMUNITY;
WORLD HEALTH ORGANIZATION;
ANALOGS AND DERIVATIVES;
DRUG EFFECTS;
ETHICS;
HEMORRHAGIC FEVER, EBOLA;
IMMUNOLOGY;
SERUM;
ANTIBODIES, VIRAL;
ANTIVIRAL AGENTS;
CYTOSINE;
EBOLAVIRUS;
HEMORRHAGIC FEVER, EBOLA;
HUMANS;
ORGANOPHOSPHONATES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SERUM;
THERAPIES, INVESTIGATIONAL;
|
|
EID: 84911862456
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.346.6212.908 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|